Business context and reporting period
Registrant: The filing is ADVENTRX Pharmaceuticals, Inc. (a development-stage specialty pharmaceutical company), not Savara Inc. It covers the unaudited quarter and nine months ended September 30, 2011; filed November 8, 2011.
The company reported no product sales or revenue in the quarter or nine-month period. Its principal development programs were ANX-188, acquired with SynthRx in April 2011, and ANX-514. Exelbine was another program, but the company had decided to stop significant additional investment in it.
Financial performance and liquidity
| Metric | Q3 2011 | Nine months 2011 | Comparable 2010 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $2.05 million | $4.00 million | $0.92 million / $2.79 million |
| Selling, general and administrative expense | $1.98 million | $5.38 million | $0.94 million / $3.42 million |
| Operating loss | $3.55 million | $10.95 million | $1.87 million / $6.23 million |
| Net loss applicable to common stock | $3.54 million ($0.13/share) | $10.89 million ($0.43/share) | $1.84 million ($0.13/share) / $11.81 million ($0.94/share) |
Gross margin was not meaningful because there was no current-period revenue. Nine-month net loss was $10.89 million, versus $6.17 million net loss in 2010; the larger 2010 loss applicable to common stock included $5.64 million of noncash deemed preferred-stock dividends.
- Cash and liquidity: September 30 cash and cash equivalents were $32.77 million, with $5.52 million in short-term investments; combined, approximately $38.3 million. Current assets were $39.04 million and current liabilities $3.12 million.
- Cash flows: Nine-month operating cash use was $10.43 million, investing cash use $5.72 million, and financing cash provided $20.96 million. Financing chiefly reflected the January 2011 equity offering.
- Debt: The balance sheet lists no outstanding debt at September 30; it reports current liabilities, including a $644,000 contingent acquisition liability.
Material changes versus the prior comparable period
- Q3 R&D expense rose about 123% year over year; nine-month R&D expense rose about 44%. SG&A increased about 110% for Q3 and 57% for nine months. Management attributed increases to development/manufacturing work, personnel, Exelbine commercial-readiness activity, and professional fees.
- Operating losses increased in both comparative periods. Nine-month net loss applicable to common stock was lower than in 2010 chiefly because 2010 included the preferred-stock deemed dividend, despite higher operating loss in 2011.
- In January 2011, ADVENTRX raised $22.5 million gross, or $21.0 million net, through a registered direct equity financing. Shares outstanding increased from 15.48 million at December 31, 2010 to 26.47 million at September 30, 2011.
- The SynthRx acquisition added ANX-188 and recorded $6.55 million of in-process R&D and $0.40 million of goodwill; preliminary estimated purchase price was $6.67 million.
Outlook, commentary, and risks
- Management expected September 30 cash and investments to fund its currently planned operations for at least 12 months, but said it may seek substantial additional capital to support ANX-188 and ANX-514 development. Financing may not be available on acceptable terms or in time.
- For ANX-188, management planned an FDA meeting in Q4 2011 on a proposed Phase 3 pediatric sickle-cell crisis study and aimed to begin the study in 2012, subject to FDA agreement. Estimated third-party development costs through NDA submission were approximately $15–25 million.
- For ANX-514, the FDA agreed in October 2011 that a proposed approximately 400-patient study could provide clinical data supporting approval without corticosteroid premedication. The company planned to initiate the study in 2012; timing, costs, safety, and regulatory outcome remained uncertain.
- FDA issued an August 2011 complete response letter for Exelbine, citing inability to verify the authenticity of products used in its pivotal bioequivalence trial and requiring the study to be repeated. ADVENTRX was seeking a partner or outside investor and had discontinued significant additional investment.
- Key risks include clinical and regulatory failure or delay, manufacturing and third-party reliance, additional financing needs, potential dilution, and inability to secure acceptable partnerships. The filing states that disclosure controls were effective and that no material change in internal control over financial reporting was identified.
Important facts for investors to verify
- Confirm the filing entity: this supplied 10-Q is for ADVENTRX Pharmaceuticals, Inc., not Savara Inc.
- Track cash burn and financing needs against the stated 12-month runway, including the cost and timing of planned trials.
- Verify FDA progress and clinical-trial start timing for ANX-188 and ANX-514, as well as manufacturing readiness.
- Assess the Exelbine response to the FDA letter and whether a partner or outside investor is secured.
- Review potential dilution: 7.78 million warrants were outstanding at September 30, and SynthRx milestone payments could involve up to 13.48 million additional shares.